Q2 EPS Estimates for Gilead Sciences Boosted by Analyst

Gilead Sciences, Inc. (NASDAQ:GILD) – Research analysts at Zacks Research raised their Q2 2025 earnings per share (EPS) estimates for shares of Gilead Sciences in a note issued to investors on Thursday, January 16th. Zacks Research analyst E. Bagri now anticipates that the biopharmaceutical company will earn $1.75 per share for the quarter, up from their previous forecast of $1.72. The consensus estimate for Gilead Sciences’ current full-year earnings is $4.36 per share. Zacks Research also issued estimates for Gilead Sciences’ Q4 2025 earnings at $1.86 EPS, FY2025 earnings at $7.12 EPS, Q3 2026 earnings at $2.19 EPS, Q4 2026 earnings at $2.03 EPS and FY2026 earnings at $7.55 EPS.

GILD has been the topic of several other research reports. Maxim Group lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. BMO Capital Markets increased their target price on Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Cantor Fitzgerald reissued a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a research note on Wednesday, December 11th. Mizuho increased their target price on Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. Finally, Truist Financial increased their target price on Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research note on Friday, November 8th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $97.96.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $91.84 on Monday. Gilead Sciences has a 52 week low of $62.07 and a 52 week high of $98.90. The business’s fifty day simple moving average is $91.75 and its 200-day simple moving average is $84.20. The firm has a market cap of $114.46 billion, a PE ratio of 1,020.44, a price-to-earnings-growth ratio of 1.27 and a beta of 0.18. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same quarter in the prior year, the company posted $2.29 EPS. The company’s quarterly revenue was up 7.0% on a year-over-year basis.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 3.35%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is 3,422.22%.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the transaction, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the transaction, the director now directly owns 8,920 shares in the company, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 456,234 shares of company stock valued at $42,130,461 over the last quarter. Company insiders own 0.29% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. nVerses Capital LLC acquired a new position in shares of Gilead Sciences in the third quarter valued at approximately $25,000. Decker Retirement Planning Inc. purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $29,000. Valued Wealth Advisors LLC boosted its stake in shares of Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 161 shares in the last quarter. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Gilead Sciences in the second quarter valued at approximately $33,000. Finally, Friedenthal Financial purchased a new stake in shares of Gilead Sciences in the third quarter valued at approximately $50,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.